Physician profile
Numthip Chitravas
NPI 1073761789
$3,350.96
in general payments reported to CMS, 2019-2025
29 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,833 · 2020: $260 · 2021: $433 · 2022: $300 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $634.05 | 2019-2021 | |
| Sk Life Science, INC. | $547.93 | 2021-2025 | Xcopri |
| Greenwich Biosciences, INC. | $224.76 | 2019-2021 | |
| Ucb, INC. | $221.01 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $214.50 | 2019-2021 | |
| Medtronic USA, INC. | $178.27 | 2019 | |
| Neuropace, INC. | $140.99 | 2019 | |
| Eisai INC. | $127.70 | 2019-2022 | |
| Pfizer INC. | $125.00 | 2025 | |
| Nevro Corp. | $115.76 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $107.91 | 2019 | |
| Grifols USA, LLC | $94.48 | 2022 | |
| Alnylam Pharmaceuticals INC. | $90.75 | 2020 | |
| Csl Behring | $68.95 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $56.67 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $50.74 | 2019 | |
| Kyowa Kirin, INC. | $47.25 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $41.05 | 2019 | |
| Supernus Pharmaceuticals, INC. | $39.01 | 2019-2021 | |
| Abbvie INC. | $33.16 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $32.20 | 2019-2020 | |
| Banner Life Sciences, LLC | $30.27 | 2021 | |
| Lilly USA, LLC | $28.96 | 2019 | |
| Biogen, INC. | $25.85 | 2020-2021 | |
| Amgen INC. | $17.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.88 | 2020 | |
| Neurelis, INC. | $14.43 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Numthip Chitravas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.